284 related articles for article (PubMed ID: 29304731)
1. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.
Tiessen RG; Kennedy CA; Keller BT; Levin N; Acevedo L; Gedulin B; van Vliet AA; Dorenbaum A; Palmer M
BMC Gastroenterol; 2018 Jan; 18(1):3. PubMed ID: 29304731
[TBL] [Abstract][Full Text] [Related]
2. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.
Palmer M; Jennings L; Silberg DG; Bliss C; Martin P
BMC Pharmacol Toxicol; 2018 Mar; 19(1):10. PubMed ID: 29548345
[TBL] [Abstract][Full Text] [Related]
3. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
Newsome PN; Palmer M; Freilich B; Sheikh MY; Sheikh A; Sarles H; Herring R; Mantry P; Kayali Z; Hassanein T; Lee HM; Aithal GP;
J Hepatol; 2020 Aug; 73(2):231-240. PubMed ID: 32234329
[TBL] [Abstract][Full Text] [Related]
4. Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice.
Salic K; Kleemann R; Wilkins-Port C; McNulty J; Verschuren L; Palmer M
PLoS One; 2019; 14(6):e0218459. PubMed ID: 31233523
[TBL] [Abstract][Full Text] [Related]
5. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
Nunez DJ; Yao X; Lin J; Walker A; Zuo P; Webster L; Krug-Gourley S; Zamek-Gliszczynski MJ; Gillmor DS; Johnson SL
Diabetes Obes Metab; 2016 Jul; 18(7):654-62. PubMed ID: 26939572
[TBL] [Abstract][Full Text] [Related]
6. Absorption, Distribution, Metabolism, and Excretion of [
Siebers N; Palmer M; Silberg DG; Jennings L; Bliss C; Martin PT
Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):91-101. PubMed ID: 28702877
[TBL] [Abstract][Full Text] [Related]
7. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation.
Graffner H; Gillberg PG; Rikner L; Marschall HU
Aliment Pharmacol Ther; 2016 Jan; 43(2):303-10. PubMed ID: 26527417
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study.
Simrén M; Bajor A; Gillberg PG; Rudling M; Abrahamsson H
Aliment Pharmacol Ther; 2011 Jul; 34(1):41-50. PubMed ID: 21545606
[TBL] [Abstract][Full Text] [Related]
9. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation.
Wong BS; Camilleri M; McKinzie S; Burton D; Graffner H; Zinsmeister AR
Am J Gastroenterol; 2011 Dec; 106(12):2154-64. PubMed ID: 21876564
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes.
Chen L; Yao X; Young A; McNulty J; Anderson D; Liu Y; Nystrom C; Croom D; Ross S; Collins J; Rajpal D; Hamlet K; Smith C; Gedulin B
Am J Physiol Endocrinol Metab; 2012 Jan; 302(1):E68-76. PubMed ID: 21934041
[TBL] [Abstract][Full Text] [Related]
12. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis.
Luo Y; Decato BE; Charles ED; Shevell DE; McNaney C; Shipkova P; Apfel A; Tirucherai GS; Sanyal AJ
JHEP Rep; 2022 Jan; 4(1):100392. PubMed ID: 34977519
[TBL] [Abstract][Full Text] [Related]
13. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
[TBL] [Abstract][Full Text] [Related]
14. [The inhibitors of the apical sodium-dependent bile acid transporter (ASBT) as promising drugs].
Saveleva EE; Tyutrina ES; Nakanishi T; Tamai I; Salmina AB
Biomed Khim; 2020 May; 66(3):185-195. PubMed ID: 32588824
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
16. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.
Mouzaki M; Wang AY; Bandsma R; Comelli EM; Arendt BM; Zhang L; Fung S; Fischer SE; McGilvray IG; Allard JP
PLoS One; 2016; 11(5):e0151829. PubMed ID: 27203081
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.
Miethke AG; Zhang W; Simmons J; Taylor AE; Shi T; Shanmukhappa SK; Karns R; White S; Jegga AG; Lages CS; Nkinin S; Keller BT; Setchell KD
Hepatology; 2016 Feb; 63(2):512-23. PubMed ID: 26172874
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes.
Wu Y; Aquino CJ; Cowan DJ; Anderson DL; Ambroso JL; Bishop MJ; Boros EE; Chen L; Cunningham A; Dobbins RL; Feldman PL; Harston LT; Kaldor IW; Klein R; Liang X; McIntyre MS; Merrill CL; Patterson KM; Prescott JS; Ray JS; Roller SG; Yao X; Young A; Yuen J; Collins JL
J Med Chem; 2013 Jun; 56(12):5094-114. PubMed ID: 23678871
[TBL] [Abstract][Full Text] [Related]
19. Prednisolone increases enterohepatic cycling of bile acids by induction of Asbt and promotes reverse cholesterol transport.
Out C; Dikkers A; Laskewitz A; Boverhof R; van der Ley C; Kema IP; Wolters H; Havinga R; Verkade HJ; Kuipers F; Tietge UJ; Groen AK
J Hepatol; 2014 Aug; 61(2):351-7. PubMed ID: 24681341
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis.
Ghallab A; González D; Strängberg E; Hofmann U; Myllys M; Hassan R; Hobloss Z; Brackhagen L; Begher-Tibbe B; Duda JC; Drenda C; Kappenberg F; Reinders J; Friebel A; Vucur M; Turajski M; Seddek AL; Abbas T; Abdelmageed N; Morad SAF; Morad W; Hamdy A; Albrecht W; Kittana N; Assali M; Vartak N; van Thriel C; Sous A; Nell P; Villar-Fernandez M; Cadenas C; Genc E; Marchan R; Luedde T; Åkerblad P; Mattsson J; Marschall HU; Hoehme S; Stirnimann G; Schwab M; Boor P; Amann K; Schmitz J; Bräsen JH; Rahnenführer J; Edlund K; Karpen SJ; Simbrunner B; Reiberger T; Mandorfer M; Trauner M; Dawson PA; Lindström E; Hengstler JG
J Hepatol; 2024 Feb; 80(2):268-281. PubMed ID: 37939855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
